Bruker Corporation - BRKR STOCK NEWS

Bruker Corporation has announced an increase in its quarterly cash dividend to $0.05 per share, up from $0.04 in Q1 2021. The new dividend will be paid on March 18, 2022, to stockholders of record as of March 1, 2022. Furthermore, the Board has approved a plan to raise its annual cash dividend from $0.16 to $0.20, contingent on quarterly Board approval beginning with this payment.

Bruker Corporation (Nasdaq: BRKR) reported Q4 2021 revenues of $683.5 million, an increase of 8.9% year-over-year, with organic growth of 11.4%. FY 2021 revenues reached $2.42 billion, up 21.7%, with non-GAAP EPS rising 55.6% to $2.10. For FY 2022, Bruker expects revenue growth between 5% to 7%, and non-GAAP EPS guidance of $2.29 to $2.33, reflecting solid performance despite ongoing supply chain challenges. Significant investments in Project Accelerate 2.0 focus on proteomics and spatial biology are expected to drive future growth.

Bruker Corporation (Nasdaq: BRKR) will participate in the 11th Annual SVB Leerink Global Healthcare Conference virtually on February 16, 2022, at 8:40 AM EST. Frank Laukien, Chairman, President & CEO, will represent the company. Interested parties can access a live audio webcast on the Investor Relations section of Bruker's website. A replay will be available for 30 days post-event. Bruker specializes in high-performance scientific instruments and solutions for life sciences and diagnostics, contributing to advancements in molecular and cellular research.

Bruker Corporation (Nasdaq: BRKR) unveiled its innovative Sierra SPR-32 Pro at the SLAS2022 International Conference, enhancing high-throughput screening (HTS) capabilities. This advanced microfluidic system allows parallel readout of 32 sensor spots, significantly expediting drug development by reducing measurement time by up to threefold. The system is ideal for characterizing biologics and small molecules, supporting complex assays with high sensitivity. Bruker's integration with automation and data transfer to analysis software streamlines research processes for drug discovery.

Bruker Corporation (Nasdaq: BRKR) has launched the timsTOF MALDI PharmaPulse®, a groundbreaking high-throughput screening system at the SLAS2022 International Conference. This innovative platform combines Trapped Ion Mobility Spectrometry and high-resolution mass spectrometry for unmatched assay specificity. With speeds of 10 kHz, it supports various HTS applications, promising to enhance drug discovery by reducing false discovery rates. The software integration allows seamless data transfer for efficient analysis and demonstrates significant advancements in drug molecule design.

Bruker Corporation (NASDAQ: BRKR) announced its acquisition of Danish company PepSep, enhancing its nanoLC offerings. This acquisition aims to optimize nanoflow proteomics workflows, particularly for Bruker’s nanoElute® UHPLC system. Additionally, Bruker established an OEM agreement with IonOpticks to produce high-performance nanoLC Aurora columns. Both PepSep and IonOpticks solutions are designed to improve the performance and ease of use of the timsTOF 4D-Proteomics solutions, which is essential for high-throughput proteomics applications.

Bruker Corporation (Nasdaq: BRKR) will report its fourth quarter and fiscal year 2021 financial results on February 11, 2022, before market opening. A conference call and webcast will follow at 8:30 a.m. EST. Investors can access the call via Bruker’s investor relations website, and a telephone replay will be available until March 11, 2022. The company specializes in high-performance scientific instruments, enabling research across various life science and industrial applications.

Bruker Corporation (Nasdaq: BRKR) has acquired Prolab Instruments GmbH, a Swiss firm specializing in high-precision low-flow liquid chromatography technology. This acquisition is expected to enhance Bruker’s capabilities in proteomics and metabolomics, integrating Prolab's unique Zirconium™ products, including the Zirconium Qube autosampler and Zirconium Ultra UHPLC systems. Prolab's innovations will improve high-performance mass spectrometry workflows, particularly for single-cell proteomics, validating Bruker's strategy in expanding its analytical solutions portfolio.

Bruker Corporation (Nasdaq: BRKR) will participate in the 40^th annual J.P. Morgan Healthcare Conference, scheduled for January 10-13, 2022. The Company’s Chairman and CEO, Frank Laukien, along with Executive Vice President and CFO, Gerald Herman, will present on January 10 at 9:00 AM EST. A live audio webcast of this presentation will be accessible on the Investor Relations section of Bruker's website, with a replay available for 30 days post-event. Bruker focuses on high-performance scientific instruments, enhancing life sciences research and diagnostics.